Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$210.28 +0.4%	$192.84	$163.81 ▼ $218.66	$370.09B	0.5	5.09 million shs	5.52 million shs
AKRX Akorn		$0.19	$0.09 ▼ $5.46	$3.60M	0.95	9.60 million shs	1.19 million shs
JNJ Johnson & Johnson	$179.10 +0.1%	$163.48	$140.68 ▼ $181.16	$430.92B	0.41	8.49 million shs	9.52 million shs
LLY Eli Lilly and Company	$710.73 +0.1%	$754.70	$623.78 ▼ $972.48	$671.81B	0.44	6.97 million shs	3.22 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.35%	+1.76%	+10.48%	+14.59%	+7.00%
AKRX Akorn	0.00%	0.00%	0.00%	0.00%	0.00%
JNJ Johnson & Johnson	+0.11%	+1.32%	+5.96%	+16.97%	+10.97%
LLY Eli Lilly and Company	+0.27%	+1.31%	-10.92%	-0.46%	-25.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.7633 of 5 stars	2.5	4.0	3.3	3.9	3.9	2.5	1.3
AKRX Akorn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	4.8476 of 5 stars	2.3	5.0	4.2	3.9	3.5	1.7	1.9
LLY Eli Lilly and Company	4.9993 of 5 stars	4.3	5.0	3.3	4.0	3.3	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.96	Moderate Buy	$214.95	2.22% Upside
AKRX Akorn	0.00	N/A	N/A	N/A
JNJ Johnson & Johnson	2.65	Moderate Buy	$176.29	-1.57% Downside
LLY Eli Lilly and Company	2.65	Moderate Buy	$950.17	33.69% Upside

Current Analyst Ratings Breakdown

Latest AKRX, LLY, JNJ, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$185.00 ➝ $200.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.59	$14.99 per share	14.03	($0.08) per share	-2,628.55
AKRX Akorn	$682.43M	0.00	N/A	0.19	$1.86 per share	0.00
JNJ Johnson & Johnson	$88.82B	4.86	$13.13 per share	13.64	$32.58 per share	5.50
LLY Eli Lilly and Company	$45.04B	14.93	$14.25 per share	49.87	$19.39 per share	36.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	100.14	15.04	1.35	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
AKRX Akorn	-$226.77M	-$0.34	N/A	N/A	N/A	-55.64%	8.53%	1.31%	N/A
JNJ Johnson & Johnson	$14.07B	$9.35	19.15	16.18	2.28	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	46.45	22.84	0.99	25.91%	92.72%	16.89%	10/29/2025 (Estimated)

Latest AKRX, LLY, JNJ, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.12%	N/A	312.38%	53 Years
AKRX Akorn	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	2.90%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.84%	N/A	39.22%	11 Years

Latest AKRX, LLY, JNJ, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
AKRX Akorn	0.09	0.50	0.32
JNJ Johnson & Johnson	0.50	1.01	0.76
LLY Eli Lilly and Company	1.86	1.28	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AKRX Akorn	64.03%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AKRX Akorn	3.90%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AKRX Akorn	2,227	133.15 million	N/A	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable

AKRX, LLY, JNJ, and ABBV Headlines

Recent News About These Companies

Analyzing Eli Lilly and Company (NYSE:LLY) & Novo Nordisk A/S (NYSE:NVO)

2 hours ago | americanbankingnews.com

Eli Lilly and Company (NYSE:LLY) Rating Increased to Strong-Buy at Wall Street Zen

3 hours ago | marketbeat.com

What Eli Lilly and Co. must achieve to get $100M in state incentives

August 22 at 8:19 PM | bizjournals.com

Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. Lisa C. McClain

August 22 at 8:10 PM | marketbeat.com

Eli Lilly's (LLY) Mounjaro Shows Potential in Reducing Cancer Risk

August 22 at 2:51 PM | gurufocus.com

Promising Pharmaceutical Stocks To Follow Now - August 21st

August 22 at 2:37 PM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Trading Up 1.5% - Should You Buy?

August 22 at 1:45 PM | marketbeat.com

Eli Lilly’s Mirikizumab Study: A Promising Step for Pediatric Ulcerative Colitis Treatment

August 22 at 12:11 PM | tipranks.com

Eli Lilly’s Pediatric Arthritis Study: A Potential Game Changer?

August 22 at 12:11 PM | tipranks.com

Eli Lilly’s New Study on LY3849891: A Potential Game-Changer for Liver Disease Treatment?

August 22 at 12:11 PM | tipranks.com

Eli Lilly’s Lebrikizumab Study: A Potential Game-Changer for Atopic Dermatitis

August 22 at 12:11 PM | tipranks.com

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

August 22 at 10:01 AM | zacks.com

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

August 22 at 9:53 AM | fool.com

Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?

August 22 at 9:50 AM | zacks.com

Ameriprise Financial Inc. Lowers Holdings in Eli Lilly and Company $LLY

August 22 at 9:00 AM | marketbeat.com

Bragg Financial Advisors Inc Has $10.33 Million Holdings in Eli Lilly and Company $LLY

August 22 at 9:00 AM | marketbeat.com

Lilly to participate in Wells Fargo 20th Annual Healthcare Conference

August 22 at 9:00 AM | prnewswire.com

Norinchukin Bank The Acquires 4,894 Shares of Eli Lilly and Company $LLY

August 22 at 8:49 AM | marketbeat.com

Eli Lilly and Company $LLY Stock Holdings Reduced by Blackhill Capital Inc.

August 22 at 8:49 AM | marketbeat.com

CW Advisors LLC Has $57.81 Million Stock Holdings in Eli Lilly and Company $LLY

August 22 at 8:11 AM | marketbeat.com

Atika Capital Management LLC Acquires 450 Shares of Eli Lilly and Company $LLY

August 22 at 7:48 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AKRX, LLY, JNJ, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$210.28 +0.78 (+0.37%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$210.12 -0.17 (-0.08%)

As of 08/22/2025 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Akorn NASDAQ:AKRX

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Johnson & Johnson NYSE:JNJ

$179.10 +0.17 (+0.09%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$179.22 +0.12 (+0.07%)

As of 08/22/2025 07:56 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$710.73 +0.91 (+0.13%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$711.10 +0.37 (+0.05%)

As of 08/22/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time